Cardiovascular outcomes of SGLT2 inhibition: evidence from recent clinical trials.

HFA Premium Access

Cardiovascular outcomes of SGLT2 inhibition: evidence from recent clinical trials.

Session: Novel strategies for addressing diabetes & heart failure: evaluating cardiovascular outcomes

Topic: Chronic heart failure

Speaker: Doctor D. Fitchett (Toronto, CA)

Organised by the Physicians Academy for Cardiovascular Education (PACE) Foundation / Course Director: Prof Adriaan A Voors / Supported by an unrestricted educational grant from Boehringer Ingelheim

Event: HEART FAILURE 2016

Congress Presentation

Add to my library

About the speaker

Doctor David Fitchett

St. Michael's Hospital, Toronto (Canada)

18 presentations

0 follower

2 more presentations in this session

Introduction.

Speaker: Professor S. Anker (Berlin, DE)

Access

Interactive case discussion: what are the clinical implications of cardiovascular outcomes of SGLT2 inhibition?

Speaker: Professor S. Anker (Berlin, DE) Doctor D. Fitchett (Toronto, CA)

Access

Access the full session

Novel strategies for addressing diabetes & heart failure: evaluating cardiovascular outcomes

Speakers: Doctor D. Fitchett, Professor S. Anker, Professor S. Anker, Doctor D. Fitchett

Access

About the event

HEART FAILURE 2016

21 May - 24 May 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources